Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tengrui Zhang"'
Autor:
Chen Li, Jiagui Song, Zhengyang Guo, Yueqing Gong, Tengrui Zhang, Jiaqi Huang, Rui Cheng, Xiaotong Yu, Yanfang Li, Li Chen, Xiaojuan Ma, Yan Sun, Yan Wang, Lixiang Xue
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
EZH2 inhibitors (EZH2i), a class of small-molecule inhibitors that target EZH2 to exert anti-tumor functions, have just been approved by the US Food and Drug Administration (FDA) in treatment of adults and adolescents with locally advanced or metasta
Externí odkaz:
https://doaj.org/article/03a344b3724248ed9d0e0cde3a386412
Autor:
Tengrui Zhang, Zhengyang Guo, Xiao Huo, Yueqing Gong, Chen Li, Jiaqi Huang, Yan Wang, Hao Feng, Xiaojuan Ma, Changtao Jiang, Qianqian Yin, Lixiang Xue
Publikováno v:
EBioMedicine, Vol 77, Iss , Pp 103872- (2022)
Summary: Background: Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy. The EZH2 inhibitor EPZ-6438 was first approved by the US Food and Drug Administration (FDA) in 2020. However, its inadequate an
Externí odkaz:
https://doaj.org/article/0662ed4407564567ac1a57d87e32c475
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 18:217-223
BACKGROUND Glioblastoma (GBM) is one of the most common primary brain tumors, which accounts up to 80% of malignant brain tumors and the 5-year relative survival rate is below 5%. Recent studies showed that the lipid metabolism played an essential ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7668834cad1f92cc2ed54f1f6e61d9bb
https://doi.org/10.1111/ajco.13574
https://doi.org/10.1111/ajco.13574
Publikováno v:
Clinical Epigenetics
Enhancer of zeste homolog 2 inhibitors (EZH2i) have garnered increased attention owing to their anticancer activity by targeting EZH2, a well-known cancer-promoting factor. However, some lymphomas are resistant to EZH2i, and EZH2i treatment alone is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d73ea53a006305b72159407bc0b651b2
https://doi.org/10.1186/s13148-021-01045-1
https://doi.org/10.1186/s13148-021-01045-1
Publikováno v:
Clinical Epigenetics
Increasing evidence has suggested that epigenetic and metabolic alterations in cancer cells are highly intertwined. As the master epigenetic regulator, enhancer of zeste homolog 2 (EZH2) suppresses gene transcription mainly by catalyzing the trimethy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1edd0f99f4d48bfa6fe4bb34514a7cdc
https://pubmed.ncbi.nlm.nih.gov/32448308
https://pubmed.ncbi.nlm.nih.gov/32448308